Eli Lilly's EBGLYSS Meets Phase 3b Endpoints in Hand and Foot Atopic Dermatitis Study

Eli Lilly (LLY) said its IL-13 inhibitor EBGLYSS (lebrikizumab-lbkz) met primary and secondary endpoints in the Phase 3b ADtouch study, positioning the drug for a potential FDA label expansion into localized hand and foot atopic dermatitis. In the 221-patient trial, 53% of EBGLYSS-treated patients achieved clear or almost clear skin on hands and feet at Week 16, versus 27% on placebo. Itch and pain improved as early as two and one weeks, respectively. Patient satisfaction with hand clearance reached 77%, compared with 40% for placebo. EBGLYSS is currently approved for moderate-to-severe atopic dermatitis in adults and children 12 and older weighing at least 40 kg. Lilly has submitted the data to the FDA for consideration of a label update covering localized hand and foot disease. LLY closed Tuesday at $1,184.63, down 0.01%.